Loading
Life sciences · Journal article
Discover Oncology · September 19, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
To assess the clinical efficacy and safety of Romiplostim N01 for moderate-to-severe Cancer Therapy-Induced Thrombocytopenia (Grade II–IV, CTIT) in a real-world study. In this retrospective analysis, a total of ten patients with a current diagnosis of CTIT were enrolled from the Department of Thoracic Oncology at the Second Affiliated Hospital of Zunyi Medical University, who received treatments from April 2024 to August 2024. All subjects were aged over 18 years, with a diagnosis of CTIT and subjected to platelet elevation with Romiplostim N01. The mean platelet count (PLT) for these patients before Romiplostim N01 administration was 28.8 × 10⁹/L. The median time to platelet recovery to 75 × 10⁹/L was 6 days, with a range of 5–13 days, and the median time to reach 100 × 10⁹/L was 7 days, the range being 5–16 days. After treatment, 70% of patients (7/10) reached a PLT count ≥ 100 × 10⁹/L; 60% of them reached this threshold within 14 days. Response rates were 40% at 7 days and 60% at 14 days. In the small exploratory cohort, Romiplostim N01 tentatively increased platelet counts in patients with grade II–IV CTIT, with no treatment-related serious adverse events reported.